SDGR

Peers: CERT RXRX RLAY ABSI TEM VEEV ABCL DNA IQV ICLR

| Held by: IJR ARKG VTI VB IWM VBK VXF IWO SPSM IJT

Index	RUT
Market Cap	1.98B
Enterprise Value	1.67B
Income	-54.34M
Sales	259.04M
Book/sh	4.40
Cash/sh	5.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	850
IPO	Feb 06, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	7.64
P/B	6.01
P/C	4.73
P/FCF	-
EV/EBITDA	-
EV/Sales	6.44
Quick Ratio	2.71
Current Ratio	2.71
Debt/Eq	0.33
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-1.45
EPS next Q	-0.67
EPS this Y	-16.60%
EPS next Y	12.00%
EPS next 5Y	13.73%
EPS past 3/5Y	12.46% -28.10%
Sales past 3/5Y	12.24% 18.81%
EPS Y/Y TTM	70.36%
Sales Y/Y TTM	8.88%
EPS Q/Q	113.42%
Sales Q/Q	7.54%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	119.30% 24.80%

Insider Own	15.38%
Insider Trans	-0.28%
Inst Own	88.21%
Inst Trans	-0.07%
ROA	-8.18%
ROE	-16.18%
ROIC	-12.92%
Gross Margin	56.87%
Oper. Margin	-59.24%
Profit Margin	-20.98%
SMA20	2.84%
SMA50	4.83%
SMA200	57.05%
Trades

Shs Outstand	65.62M
Shs Float	63.30M
Short Float	16.43%
Short Ratio	5.23
Short Interest	10.40M
52W High	33.78 -21.67%
52W Low	10.94 141.75%
Volatility	10.02% 8.54%
ATR (14)	2.07
RSI (14)	51.08
Beta	1.66
Rel Volume	0.30
Avg Volume	1.99M
Volume	30,021

Perf Week	-0.97%
Perf Month	-18.83%
Perf Quarter	61.34%
Perf Half Y	105.59%
Perf YTD	47.99%
Perf Year	28.76%
Perf 3Y	-6.63%
Perf 5Y	-55.34%
Perf 10Y	-
Recom	1.57
Target Price	25.86
Prev Close	26.19
Price	26.46
Change %	1.03%

Consensus

Buy

Avg. Price Target

$25.86

Implied Upside

-2.3%

Analysts12incl. previous ratings

Rating Distribution8 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 14, 2026	Resumed	UUBS	Neutral	$19	-28.2%
Dec 15, 2025	Upgrade	BBofA Securities	Neutral → Buy	$24	-9.3%
Sep 30, 2025	Initiated	GGoldman	Neutral	$19	-28.2%
Aug 15, 2025	Downgrade	CCitigroup	Buy → Neutral	$20	-24.4%
Aug 14, 2025	Initiated	BBarclays	Overweight	$25	-5.5%
Jul 03, 2025	Resumed	MMorgan Stanley	Equal-Weight	$28	+5.8%
Jul 02, 2024	Initiated	LLeerink Partners	Outperform	$29	+9.6%
Dec 05, 2023	Initiated	KKeyBanc Capital Markets	Overweight	$38	+43.6%
May 05, 2023	Resumed	PPiper Sandler	Overweight	$60	+126.8%
Dec 19, 2022	Initiated	GGoldman	Neutral	$23	-13.1%
Mar 01, 2022	Initiated	CCitigroup	Buy	$55	+107.9%
Nov 19, 2021	Initiated	PPiper Sandler	Overweight	$87	+228.8%
Nov 19, 2021	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$82 → $49	+85.2%
Nov 11, 2021	Downgrade	BBofA Securities	Buy → Neutral	$80 → $52	+96.5%
Oct 13, 2021	Initiated	BBerenberg	Buy	$91	+243.9%
Sep 01, 2021	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$82	+209.9%
May 25, 2021	Initiated	CCraig Hallum	Buy	$85	+221.2%
Nov 23, 2020	Upgrade	BBofA Securities	Neutral → Buy	$74	+179.7%
Oct 12, 2020	Upgrade	JJefferies	Hold → Buy
Mar 02, 2020	Initiated	MMorgan Stanley	Equal-Weight	$43	+62.5%

Oct-28-26 08:30AM	Schrodinger to Present at UBS Global Healthcare Conference (Business Wire) +15.53%
Oct-27-26 08:08PM	Schrodinger's Hosted Shift Faces Its Toughest Test As Revenue Is Expected To Shrink (Earnings Whispers) +9.06%
Oct-26-26 08:30AM	Schrodinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrdinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-21-26 08:30AM	Schrodinger to Announce Third Quarter 2026 Financial Results on November 4 (Business Wire)
08:30AM	Loading…
08:30AM	Schrdinger to Announce Third Quarter 2026 Financial Results on November 4 (Business Wire)
Oct-14-26 11:05AM	Schrodinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry (Business Wire)
11:05AM	Schrdinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry (Business Wire)
Oct-08-26 07:58PM	What Could Go Wrong With Recursion Pharmaceuticals Stock? (Trefis)
Sep-17-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +26.37%
Sep-14-26 10:00AM	AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 (PR Newswire) +9.10%
Sep-09-26 07:00AM	Schrodinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs (Business Wire)
Sep-03-26 08:55AM	AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 (PR Newswire)
Sep-01-26 08:30AM	Schrodinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire) +6.87%
08:30AM	Schrdinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
08:30AM	Loading…
Aug-14-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-06-26 01:08AM	Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ... (GuruFocus.com) +8.60%
Aug-05-26 08:30AM	Schrodinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery (Business Wire)
08:30AM	Schrdinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery (Business Wire)
Jul-27-26 07:30AM	Schrodinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery (Business Wire)
07:30AM	Schrdinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery (Business Wire)
Jul-23-26 09:05AM	An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
Jul-22-26 08:30AM	Schrodinger to Announce Second Quarter 2026 Financial Results on August 5 (Business Wire)
Jul-20-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-26 09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-16-26 08:45AM	The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It (PR Newswire)
May-22-26 08:30AM	Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-26 04:05PM	Schrdinger Reports First Quarter 2026 Financial Results (Business Wire)
08:30AM	Loading…
May-04-26 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
Apr-21-26 08:30AM	Schrdinger to Announce First Quarter 2026 Financial Results on May 5 (Business Wire)
Apr-17-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-02-26 12:13PM	Can AI Acceleration and R&D Strength Drive VEEV Ahead of Q4 Earnings? (Zacks)
02:57AM	Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth (Insider Monkey)
Feb-26-26 03:08AM	Schrodinger Q4 Earnings Call Highlights (MarketBeat) +8.14%
12:03AM	Schrodinger Inc (SDGR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Transition ... (GuruFocus.com)
Feb-25-26 04:05PM	Schrdinger Reports Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
10:00AM	Nvidia Earnings Slam Into Market With No Patience for AI Hiccups (Bloomberg)
Feb-24-26 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
Feb-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-12-26 05:30PM	10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -5.59%
Feb-11-26 08:30AM	Schrdinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25 (Business Wire) -12.11%
Feb-03-26 03:38AM	TruBridge (TBRG) Surges 5.6%: Is This an Indication of Further Gains? (Zacks) -5.04%
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
Jan-12-26 08:30AM	Schrodinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities (Business Wire)
Jan-09-26 07:00AM	Schrodinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign (Business Wire)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-02-26 12:10PM	CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus (Zacks)
Dec-31-25 10:30AM	KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic (Zacks)
Dec-23-25 12:35PM	FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform (Zacks)
09:48AM	Do Options Traders Know Something About Schrodinger Stock We Don't? (Zacks)
Dec-22-25 09:53AM	BofA Upgrades Schrodinger (SDGR) to Buy After Strategic Pivot to Software (Insider Monkey) +9.80%
Dec-20-25 06:35AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Dec-17-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-12-25 09:55AM	Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-10-25 09:55AM	Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-07-25 02:26AM	Schrodinger (SDGR) and Copernic Catalysts Surpass the Final Technical Milestone for Neptune (Insider Monkey)
Nov-06-25 08:30AM	Schrodinger to Present at Jefferies London Healthcare Conference (Business Wire) -5.67%
12:06AM	Schrodinger Inc (SDGR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... (GuruFocus.com)
Nov-05-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Third Quarter 2025 Financial Results (Business Wire)
07:15AM	Meta Slumps on AI Spending, Echoing 2022 Metaverse Rout (Bloomberg)
Nov-04-25 05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:58AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q3 2025 Result (GuruFocus.com)
Oct-30-25 07:30AM	Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrodinger (Business Wire)
Oct-22-25 08:30AM	Schrodinger to Announce Third Quarter 2025 Financial Results on November 5 (Business Wire)
Oct-21-25 07:05AM	Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength? (Zacks) -5.05%
Oct-15-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
Sep-18-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-25 09:55AM	Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:30AM	Schrodinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-15-25 04:30PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-14-25 07:00AM	Schrödinger Announces Discontinuation of SGR-2921 Program (Business Wire)
07:00AM	Schrodinger Announces Discontinuation of SGR-2921 Program (Business Wire)
Aug-06-25 06:30PM	Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 06:05PM	Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates (Zacks)
09:52AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result (GuruFocus.com)
Aug-01-25 12:08PM	Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition? (Zacks)
Jul-25-25 08:30AM	Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
08:30AM	Schrodinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-24-25 10:00AM	Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
10:00AM	Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 08:00AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-17-25 08:00AM	Ajax Therapeutics and Schrdinger Expand Research Collaboration to Include Additional JAK Target (Business Wire)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage on Schrodinger (SDGR) Stock (Insider Monkey)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-04-25 09:45AM	Meta upgraded, PNC Financial downgraded: Wall Streets top analyst calls (TipRanks)
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
08:35AM	MS initiates coverage on AI Biotechs, flags key pipeline catalysts (Investing.com)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jun-27-25 08:00AM	Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Akinsanya Karen	See Remarks	Sep 17 '26	Option Exercise	4.34	31,599	137,140	101,555	Sep 21 05:15 PM
Akinsanya Karen	See Remarks	Sep 17 '26	Sale	29.37	31,599	927,970	69,956	Sep 21 05:15 PM
KAREN OLUFUNMILYO AKINSANYA-AK	Officer	Sep 17 '26	Proposed Sale	23.93	31,599	756,164		Sep 17 04:27 PM
Jain Rachit	EVP & CFO	Jul 16 '26	Sale	15.60	875	13,647	50,877	Jul 17 05:09 PM
Jain Rachit	Officer	Jul 16 '26	Proposed Sale	15.60	875	13,647		Jul 16 03:19 PM
Aklian Mannix Vartan	Officer	Jul 01 '26	Proposed Sale	16.68	1,136	18,949		Jul 01 03:19 PM
Herman Jenny	Officer	May 01 '26	Proposed Sale	12.26	1,957	24,000		May 01 03:18 PM
Farid Ramy	President & CEO	Apr 17 '26	Option Exercise	3.07	117,527	360,808	405,351	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 16 '26	Option Exercise	3.07	43,000	132,010	373,824	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 16 '26	Sale	12.33	43,000	530,233	330,824	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 17 '26	Sale	12.21	43,000	524,944	330,824	Apr 17 06:09 PM
Jain Rachit	EVP & CFO	Apr 16 '26	Sale	12.75	844	10,758	51,752	Apr 17 06:07 PM
RAMY SAMIR FARID	Director	Apr 16 '26	Proposed Sale	12.40	86,000	1,066,400		Apr 16 04:14 PM
Jain Rachit	Officer	Apr 16 '26	Proposed Sale	12.75	844	10,758		Apr 16 03:10 PM
Herman Jenny	CAO	Mar 05 '26	Sale	12.85	775	9,956	35,412	Mar 06 05:29 PM
Herman Jenny	CAO	Mar 06 '26	Sale	12.84	608	7,808	34,804	Mar 06 05:29 PM
Jain Rachit	EVP & CFO	Mar 05 '26	Sale	12.90	1,631	21,033	52,596	Mar 06 05:29 PM
Tran Yvonne	EVP, CLO & CPO	Mar 05 '26	Sale	12.89	1,094	14,107	52,683	Mar 06 05:28 PM
Farid Ramy	President & CEO	Mar 05 '26	Sale	12.91	3,661	47,249	330,824	Mar 06 05:28 PM
Akinsanya Karen	See Remarks	Mar 05 '26	Sale	12.90	1,366	17,625	69,956	Mar 06 05:27 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Mar 05 '26	Sale	12.90	1,222	15,761	89,241	Mar 06 05:26 PM
Abel Robert Lorne	See Remarks	Mar 04 '26	Sale	12.81	1,300	16,653	55,897	Mar 06 05:26 PM
Herman Jenny	Officer	Mar 06 '26	Proposed Sale	12.84	608	7,808		Mar 06 03:18 PM
Lorton Kenneth Patrick	Officer	Mar 05 '26	Proposed Sale	12.90	1,222	15,762		Mar 05 03:27 PM
Tran Yvonne	Officer	Mar 05 '26	Proposed Sale	12.89	1,094	14,107		Mar 05 03:16 PM
Herman Jenny	Officer	Mar 05 '26	Proposed Sale	12.85	775	9,955		Mar 05 03:16 PM
Farid Ramy	Officer	Mar 05 '26	Proposed Sale	12.91	3,661	47,248		Mar 05 03:14 PM
Jain Rachit	Officer	Mar 05 '26	Proposed Sale	12.90	1,631	21,034		Mar 05 03:07 PM
Akinsanya Karen	Officer	Mar 05 '26	Proposed Sale	12.90	1,366	17,625		Mar 05 03:05 PM
Robert Abel	Officer	Mar 04 '26	Proposed Sale	12.73	1,300	16,549		Mar 04 10:21 AM
Farid Ramy	Officer	Mar 02 '26	Proposed Sale	11.90	5,560	66,151		Mar 02 05:06 PM
Akinsanya Karen	Officer	Mar 02 '26	Proposed Sale	11.99	2,206	26,454		Mar 02 04:35 PM
Tran Yvonne	EVP, CLO & CPO	Feb 10 '26	Sale	13.80	776	10,705	22,859	Feb 12 04:23 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Feb 10 '26	Sale	13.73	925	12,704	52,651	Feb 12 04:22 PM
Herman Jenny	CAO	Feb 10 '26	Sale	13.79	752	10,370	26,597	Feb 12 04:21 PM
Abel Robert Lorne	See Remarks	Feb 09 '26	Sale	13.51	1,230	16,617	19,385	Feb 11 06:00 PM
Herman Jenny	Officer	Feb 10 '26	Proposed Sale	13.79	752	10,370		Feb 10 03:40 PM
Lorton Kenneth Patrick	Officer	Feb 10 '26	Proposed Sale	13.73	925	12,704		Feb 10 03:35 PM
Tran Yvonne	Officer	Feb 10 '26	Proposed Sale	13.80	776	10,705		Feb 10 03:29 PM
Robert Abel	Officer	Feb 09 '26	Proposed Sale	13.43	1,230	16,519		Feb 09 03:21 PM

Schrodinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

CEODr. Ramy Farid Ph.D.

PresidentDr. Karen Akinsanya Ph.D.

Co-FounderDr. Richard A. Friesner Ph.D.

Executive VPMr. Richie Jain

Corporate SecretaryMs. Yvonne Tran Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Schrodinger Inc

Upgrade your Finviz experience